Other languages 10x Genomics, Inc.

Equities

TXG

US88025U1097

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
29.28 ^USD	+3.10%		+6.16%	-47.68%

04-30	Earnings Flash (TXG) 10X GENOMICS Reports Q1 Revenue $141M, vs. Street Est of $142.1M	MT
04-29	Canaccord Genuity Adjusts Price Target on 10x Genomics to $50 From $65, Maintains Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay	03-26
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel	03-21
10x Genomics Launches Two New Products With Single Cell Technology	03-13
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products	03-13
10x Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15
10x Genomics Q4 Net Loss Widens, Revenue Increases; Issues Outlook	02-15
10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15
10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024	02-15
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology	02-07
NanoString Starts Chapter 11 Bankruptcy; Exploring Strategic Options, Including Potential Sale	02-05
James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024	01-16
10x Genomics Reports Preliminary Q4, Full Year 2023 Revenue	01-08
10x Genomics Launches Network to Accelerate Access to Xenium Proof-of-Concept Data	12-21
10x Genomics Insider Sold Shares Worth $619,494, According to a Recent SEC Filing	11-22
NanoString Technologies Withdraws Q4, Full-Year Outlook Following Jury's Verdict in Patent Dispute With 10x Genomics	11-20
OWKIN Integrates 10x Genomics, Inc. Spatial Omics and Single-Cell Technologies to the MOSAIC Study	11-06
10X Genomics, Inc. Raises Revenue Guidance for Full Year 2023	11-02
10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
10X Genomics, Inc. Announces Study Fueled by Xenium Analysis Sheds Light on Resistance Mechanisms in Model of Lethal Pediatric Brain Tumors	23-10-26
NanoString Technologies Preliminary Q3 Sales Top Guidance; EU Court Declines Second Injunction in 10x Genomics Dispute	23-10-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 10x Genomics, Inc.

Equities

TXG

US88025U1097

Other languages

Filters